Methicillin-resistant Staphylococcus aureus toxic shock syndrome [3]

Emerging Infectious Diseases

Volumn 11, Issue 4, 2005, Pages 636-637

  Jamart, Sophie ^a,b   Denis, Olivier ^a   Deplano, Ariane ^a   Tragas, Georgios ^a   Vandergheynst, Alexandra ^a   De Bels, David ^a   Devriendt, Jacques ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; DOPAMINE; INFUSION FLUID; METICILLIN; STAPHYLOCOCCUS TOXIN; TEICOPLANIN; TOXIC SHOCK SYNDROME TOXIN 1;

ADULT; BACTERIOLOGY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; EUROPE; FEMALE; HUMAN; INFECTION RISK; JAPAN; LABORATORY TEST; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR TYPING; PHYSICAL EXAMINATION; TOXIC SHOCK SYNDROME; TREATMENT OUTCOME; UNITED STATES;

EID: 16244422635     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1104.040893     Document Type: Letter

References (11)

1. Furukawa Y, Segawa Y, Masuda K, Takahashi M, Ootsuka A, Hirai K, et al. Clinical experience of 3 cases of toxic shock syndrome caused by methicillin cephem-resistant Staphylococcus aureus (MRSA). Kansenshogaku Zasshi. 1986;60:1147-53.
2. Meyer RD, Monday SR, Bohach GA, Schlievert PM. Prolonged course of toxic shock syndrome associated with methicillin-resistant Staphylococcus aureus enterotoxins G and I. Int J Infect Dis. 2001;5:163-6.
3. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128-32.
4. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect Dis. 2002;2:180-9.
5. Kikuchi K, Takahashi N, Piao C, Totsuka K, Nishida H, Uchiyama T. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards. J Clin Microbiol. 2003;41:3001-6.
6. Denis O, Deplano A, Nonhoff C, De Ryck R, de Mendonca R, Rottiers S, et al. National surveillance of methicillin-resistant Staphylococcus aureus (MRSA) in Belgian hospitals in 2001 indicates rapid diversification of epidemic clones. Antimicrob Agents Chemother. 2004;48:3625-9.
7. Schmitz FJ, MacKenzie CR, Geisel R, Wagner S, Idel H, Verhoef J, et al. Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strains. Eur J Epidemiol. 1997;13:699-708.
8. van der Mee-Marquet N, Lina G, Quentin R, Yaouanc-Lapalle H, Fievre C, Takahashi N, et al. Staphylococcal exanthematous disease in a newbom due to a virulent methicillin-resistant Staphylococcus aureus strain containing the TSST-1 gene in Europe: an alert for neonatologists. J Clin Microbiol. 2003;41:4883-4.
9. Waldvogel FA. Staphylococcus aureus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000. p. 2069-92.
10. Sanford JP, Gilbert DN, Moellering RC Jr, Sande MA. The Sanford guide to antimicrobial therapy. 17th ed., Belgian/Luxemburg version. Hyde Park (VT): Antimicrobial Therapy, Inc.; 2003.
11. Issa NC, Thompson RL. Staphylococcal toxic shock syndrome. Postgrad Med. 2001;110:55-62.